CoMind raises £75m funding led by Plural to bring non-invasive brain monitoring device to market

London-based medical technology company CoMind has raised £75m in Series A funding to advance development of its non-invasive brain monitoring system for use in critical care.

The investment round was led by Plural, alongside Angelini Ventures, LocalGlobe, Octopus Ventures, Crane, Backed VC and Entrepreneur First. The new capital will support completion of clinical trials, expansion of manufacturing, and progress towards regulatory approval for the company’s first product, CoMind One.

Founded in 2018 by engineer and neuroscientist James Dacombe, CoMind is building technology that provides real-time insights into brain function without requiring invasive surgery. Its device measures cerebral blood flow, intracranial pressure and autoregulation, offering clinicians more detailed data to guide treatment decisions for patients in intensive care.

Traditional brain monitoring techniques often involve drilling into the skull to insert probes, which, while accurate, carry significant risks and costs. Non-invasive approaches such as ultrasound or near-infrared spectroscopy are safer but can be unreliable. CoMind’s system aims to bridge this gap by combining advanced optical sensors with data analytics to deliver continuous bedside monitoring.

The company said the funding will help bring its device closer to hospitals and enable doctors to better manage patients suffering from trauma, stroke and other neurological conditions. It also sees potential for its technology to contribute to research into brain disorders through continuous and precise measurement.

CoMind is now working towards regulatory submission for CoMind One and expanding its partnerships with hospitals and manufacturing partners ahead of commercial rollout.